1h Free Analyst Time
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Soluble guanylyl cyclase (sGC) is the known receptor for nitric oxide. Binding of nitric oxide to the heme moiety of the cyclase induces its capacity to synthesize the second messenger cGMP. Although the changes in the state of the heme moiety upon exposure of enzyme to NO and its correlation to the stimulation of sGC catalytic activity.Speak directly to the analyst to clarify any post sales queries you may have.
Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) pipeline Target constitutes close to 31 molecules. Out of which approximately 28 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 5, 6 and 13 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Ophthalmology, Metabolic Disorders, Genito Urinary System And Sex Hormones, Infectious Disease, Oncology, Gastrointestinal, Respiratory, Central Nervous System, Hematological Disorders, Dermatology, Immunology and Musculoskeletal Disorders which include indications Glaucoma, Pulmonary Arterial Hypertension, Chronic Kidney Disease (Chronic Renal Failure), Coronavirus Disease 2019 (COVID-19), Chronic Thromboembolic Pulmonary Hypertension, Diabetic Nephropathy, Hypertension, Neuroinflammation, Ocular Hypertension, Pulmonary Hypertension, Sickle Cell Disease With Vaso-Occlusive Crisis, Acute Heart Failure, Acute Respiratory Distress Syndrome, Alzheimer's Disease, Asthma, Brain Cancer, Chronic Obstructive Pulmonary Disease (COPD), Cirrhosis, Cognitive Impairment Associated With Schizophrenia (CIAS), Colorectal Cancer, Critical Limb Ischemia, Diabetic Foot Ulcers, Diabetic Retinopathy, Diastolic Heart Failure, Dry (Atrophic) Macular Degeneration, Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Hypertension, Inflammatory Bowel Disease, Ischemic Stroke, Kidney Disease (Nephropathy), Liver Fibrosis, MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes), Mitochondrial Diseases, Mycobacterium Infections, Non-Alcoholic Steatohepatitis (NASH), Non-Proliferative Diabetic Retinopathy (NPDR), Open-Angle Glaucoma, Osteoporosis, Pancreatic Cancer, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Pneumonia, Portal Hypertension, Pressure Ulcers, Prostate Cancer, Raynauds Disease, Schizophrenia, Skin Ulcers, Stable Angina, Stroke, Systemic Sclerosis (Scleroderma), Triple-Negative Breast Cancer (TNBC), Unspecified Cardiovascular Disorders and Vascular Dementias.
The latest report Soluble Guanylate Cyclase - Drugs In Development, 2022, outlays comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)
- The report reviews Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Overview
- Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Companies Involved in Therapeutics Development
- Akebia Therapeutics Inc
- AntiRadical Therapeutics LLC
- Bayer AG
- Boehringer Ingelheim International GmbH
- Cyclerion Therapeutics Inc
- Gurus BioPharm Inc
- Innovative Pharmacology Research
- Merck & Co Inc
- NicOx SA
- Nitric Oxide Innovations LLC
- Novartis AG
- Novoteris LLC
- Toa Eiyo Ltd
- Topadur Pharma AG
- Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Drug Profiles
- A-8R - Drug Profile
- Product Description
- Mechanism Of Action
- BAY-1211163 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BAY-1237592 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BAY-3283142 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BAY-546544 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BI-685509 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CY-3018 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CY-6463 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- GRS - Drug Profile
- Product Description
- Mechanism Of Action
- GUR-501 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- GUR-602 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MK-5475 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- mosliciguat - Drug Profile
- Product Description
- Mechanism Of Action
- naproxcinod - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NCX-470 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NCX-667 SR - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- nitric oxide - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- nitric oxide - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- olinciguat - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- praliciguat - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- riociguat - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- runcaciguat - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Activate sGC for Osteoporosis - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Activate Soluble Guanylate Cyclase for Glaucoma - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Activate Soluble Guanylate Cyclase for Glaucoma - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Activate Soluble Guanylate Cyclase for Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- TOPN-53 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TOPT-5 - Drug Profile
- Product Description
- Mechanism Of Action
- TOPV-122 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TY-55002 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Vacno - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- vericiguat - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Dormant Products
- Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Discontinued Products
- Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Product Development Milestones
- Featured News & Press Releases
- Oct 06, 2022: Cyclerion announces mitochondrial disease-focused corporate strategy
- Sep 29, 2022: Bayer launches vericiguat (Verquvo) in India, the first novel treatment approved to reduce the risk of cardiovascular deaths and repeated hospitalizations
- Sep 19, 2022: Nicox announces last patients complete final visit in NCX 470 phase 3 Mont Blanc glaucoma trial
- Jul 28, 2022: Cyclerion Therapeutics announces positive topline clinical data for CY6463 in patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
- Jul 07, 2022: Nicox announces publication of NCX 470 results demonstrating improvements to ocular hemodynamics and retinal cell physiology
- Jun 28, 2022: Cyclerion Therapeutics provides additional positive CY6463 MELAS clinical data at a webina hosted by United Mitochondrial Disease Foundation
- Jun 22, 2022: Cyclerion Therapeutics to discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation
- Jun 17, 2022: Cyclerion Therapeutics announces CY6463 data demonstrating improved cellular energetics in preclinical models of mitochondrial disease
- Jun 10, 2022: Cyclerion Therapeutics announces positive topline clinical data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium
- Jun 06, 2022: Cyclerion Therapeutics to share CY6463 MELAS topline study results, CHOP to present CY6463 preclinical data at UMDF Mitochondrial Medicine 2022 Symposium
- Jun 03, 2022: Nicox accelerates topline results from NCX 470 Mont Blanc phase 3 glaucoma trial to November 2022
- May 19, 2022: Verquvo (vericiguat) approved in China to treat patients with chronic heart failure and reduced ejection fraction
- May 17, 2022: New therapeutic option to reduce risk of cardiovascular deaths and repeated hospitalizations among adult heart failure patients approved in Singapore
- May 04, 2022: Cyclerion announces CY6463 clinical pipeline progress
- May 02, 2022: Nicox at ARVO 2022: Presentation of new non-clinical evidence of improved hemodynamic and retinal cell physiology on NCX 470
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indications, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Akebia Therapeutics Inc, 2022
- Pipeline by AntiRadical Therapeutics LLC, 2022
- Pipeline by Bayer AG, 2022
- Pipeline by Boehringer Ingelheim International GmbH, 2022
- Pipeline by Cyclerion Therapeutics Inc, 2022
- Pipeline by Gurus BioPharm Inc, 2022
- Pipeline by Innovative Pharmacology Research, 2022
- Pipeline by Merck & Co Inc, 2022
- Pipeline by NicOx SA, 2022
- Pipeline by Nitric Oxide Innovations LLC, 2022
- Pipeline by Novartis AG, 2022
- Pipeline by Novoteris LLC, 2022
- Pipeline by Toa Eiyo Ltd, 2022
- Pipeline by Topadur Pharma AG, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Akebia Therapeutics Inc
- AntiRadical Therapeutics LLC
- Bayer AG
- Boehringer Ingelheim International GmbH
- Cyclerion Therapeutics Inc
- Gurus BioPharm Inc
- Innovative Pharmacology Research
- Merck & Co Inc
- NicOx SA
- Nitric Oxide Innovations LLC
- Novartis AG
- Novoteris LLC
- Toa Eiyo Ltd
- Topadur Pharma AG
